questionsmedicales.fr
Composés chimiques organiques
Composés organiques du phosphore
Phosphoramides
Moutardes phosphoramide
Cyclophosphamide
Cyclophosphamide : Questions médicales fréquentes
Diagnostic
5
Cyclophosphamide
Chimiothérapie
Tests de laboratoire
Fonction rénale
Marqueurs tumoraux
Cancer
Surveillance médicale
Effets secondaires
Symptômes
5
Effets secondaires
Nausées
Infections
Immunosuppression
Réaction allergique
Eruptions cutanées
Thrombocytopénie
Saignements
Consultation urgente
Douleurs thoraciques
Prévention
5
Prévention des effets secondaires
Hydratation
Précautions alimentaires
Nutrition
Fertilité
Effets sur la reproduction
Vaccinations
Prévention des infections
Gestion du stress
Soutien psychologique
Traitements
5
Chimiothérapie combinée
Cyclophosphamide
Mécanisme d'action
Cellules cancéreuses
Durée du traitement
Cancer
Antiémétiques
Antibiotiques
Hydratation
Toxicité rénale
Complications
5
Cancers secondaires
Maladies cardiaques
Cardiomyopathie
Effets à long terme
Infertilité
Effets sur la reproduction
Surveillance médicale
Tests sanguins
Facteurs de risque
5
Facteurs de risque
Antécédents médicaux
Tabagisme
Effets secondaires
Interactions médicamenteuses
Cyclophosphamide
Antécédents familiaux
Cancers secondaires
Statut immunitaire
Effets secondaires
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cyclophosphamide : Questions médicales les plus fréquentes",
"headline": "Cyclophosphamide : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cyclophosphamide : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-31",
"dateModified": "2025-11-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cyclophosphamide"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Moutardes phosphoramide",
"url": "https://questionsmedicales.fr/mesh/D010752",
"about": {
"@type": "MedicalCondition",
"name": "Moutardes phosphoramide",
"code": {
"@type": "MedicalCode",
"code": "D010752",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.705.672.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cyclophosphamide",
"alternateName": "Cyclophosphamide",
"code": {
"@type": "MedicalCode",
"code": "D003520",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Saima Humayun",
"url": "https://questionsmedicales.fr/author/Saima%20Humayun",
"affiliation": {
"@type": "Organization",
"name": "Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan."
}
},
{
"@type": "Person",
"name": "Hiromu Tanigawa",
"url": "https://questionsmedicales.fr/author/Hiromu%20Tanigawa",
"affiliation": {
"@type": "Organization",
"name": "26391Showa Pharmaceutical University."
}
},
{
"@type": "Person",
"name": "Masayoshi Hirohara",
"url": "https://questionsmedicales.fr/author/Masayoshi%20Hirohara",
"affiliation": {
"@type": "Organization",
"name": "26391Showa Pharmaceutical University."
}
},
{
"@type": "Person",
"name": "Yoshinori Marutani",
"url": "https://questionsmedicales.fr/author/Yoshinori%20Marutani",
"affiliation": {
"@type": "Organization",
"name": "Division of Pharmacy, 38261Tokai University Medical Hospital."
}
},
{
"@type": "Person",
"name": "Yuji Suzuki",
"url": "https://questionsmedicales.fr/author/Yuji%20Suzuki",
"affiliation": {
"@type": "Organization",
"name": "Division of Pharmacy, 38261Tokai University Medical Hospital."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.",
"datePublished": "2024-10-22",
"url": "https://questionsmedicales.fr/article/39437137",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1056/EVIDoa2300354"
}
},
{
"@type": "ScholarlyArticle",
"name": "Studying the effect of hyperoside on recovery from cyclophosphamide induced oligoasthenozoospermia.",
"datePublished": "2023-08-14",
"url": "https://questionsmedicales.fr/article/37578152",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/19396368.2023.2241600"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of letermovir in HLA-haploidentical hematopoietic transplantation with posttransplant cyclophosphamide.",
"datePublished": "2023-07-19",
"url": "https://questionsmedicales.fr/article/37468771",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12185-023-03635-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders.",
"datePublished": "2023-05-29",
"url": "https://questionsmedicales.fr/article/37300950",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jns.2023.120693"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.",
"datePublished": "2023-03-28",
"url": "https://questionsmedicales.fr/article/36990221",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtct.2023.03.028"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés organiques du phosphore",
"item": "https://questionsmedicales.fr/mesh/D009943"
},
{
"@type": "ListItem",
"position": 4,
"name": "Phosphoramides",
"item": "https://questionsmedicales.fr/mesh/D063088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Moutardes phosphoramide",
"item": "https://questionsmedicales.fr/mesh/D010752"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cyclophosphamide",
"item": "https://questionsmedicales.fr/mesh/D003520"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cyclophosphamide - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cyclophosphamide",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-02-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cyclophosphamide",
"description": "Comment le cyclophosphamide est-il administré ?\nQuels tests sont nécessaires avant traitement ?\nLe cyclophosphamide est-il utilisé pour tous les cancers ?\nQuels marqueurs tumoraux sont surveillés ?\nLe cyclophosphamide nécessite-t-il une surveillance ?",
"url": "https://questionsmedicales.fr/mesh/D003520#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cyclophosphamide",
"description": "Quels sont les effets secondaires courants ?\nLe cyclophosphamide cause-t-il des infections ?\nQuels symptômes indiquent une réaction allergique ?\nLe cyclophosphamide provoque-t-il des saignements ?\nQuels symptômes nécessitent une consultation urgente ?",
"url": "https://questionsmedicales.fr/mesh/D003520#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cyclophosphamide",
"description": "Comment minimiser les effets secondaires ?\nY a-t-il des précautions alimentaires à prendre ?\nLe cyclophosphamide affecte-t-il la fertilité ?\nDes vaccinations sont-elles nécessaires avant traitement ?\nComment gérer le stress pendant le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D003520#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cyclophosphamide",
"description": "Le cyclophosphamide est-il utilisé seul ?\nComment le cyclophosphamide agit-il contre le cancer ?\nQuelle est la durée du traitement ?\nDes médicaments sont-ils prescrits pour les effets secondaires ?\nLe cyclophosphamide nécessite-t-il une hydratation ?",
"url": "https://questionsmedicales.fr/mesh/D003520#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cyclophosphamide",
"description": "Quelles sont les complications à long terme ?\nLe cyclophosphamide peut-il causer des problèmes cardiaques ?\nQuels sont les risques d'infertilité ?\nDes troubles sanguins peuvent-ils survenir ?\nComment surveiller les complications ?",
"url": "https://questionsmedicales.fr/mesh/D003520#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cyclophosphamide",
"description": "Qui est à risque de complications ?\nLe tabagisme influence-t-il le traitement ?\nY a-t-il des interactions médicamenteuses à surveiller ?\nLes antécédents familiaux de cancer sont-ils un facteur ?\nLe statut immunitaire affecte-t-il le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D003520#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le cyclophosphamide est-il administré ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est généralement administré par voie intraveineuse ou orale."
}
},
{
"@type": "Question",
"name": "Quels tests sont nécessaires avant traitement ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins pour évaluer la fonction rénale et hépatique sont requis."
}
},
{
"@type": "Question",
"name": "Le cyclophosphamide est-il utilisé pour tous les cancers ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il est principalement utilisé pour les lymphomes, leucémies et certains sarcomes."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont surveillés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs varient selon le type de cancer, comme le CA-125 pour l'ovaire."
}
},
{
"@type": "Question",
"name": "Le cyclophosphamide nécessite-t-il une surveillance ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance régulière des effets secondaires et de la réponse au traitement est essentielle."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les nausées, vomissements, et la perte de cheveux sont fréquents."
}
},
{
"@type": "Question",
"name": "Le cyclophosphamide cause-t-il des infections ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut réduire l'immunité, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une réaction allergique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons ou difficultés respiratoires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le cyclophosphamide provoque-t-il des saignements ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut entraîner des saignements dus à une thrombocytopénie."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent une consultation urgente ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques, des saignements inhabituels ou des signes d'infection."
}
},
{
"@type": "Question",
"name": "Comment minimiser les effets secondaires ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une bonne hydratation et des médicaments préventifs peuvent aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des précautions alimentaires à prendre ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les aliments crus et privilégier une alimentation équilibrée."
}
},
{
"@type": "Question",
"name": "Le cyclophosphamide affecte-t-il la fertilité ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut affecter la fertilité, des conseils en fertilité sont recommandés."
}
},
{
"@type": "Question",
"name": "Des vaccinations sont-elles nécessaires avant traitement ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des vaccinations peuvent être recommandées pour prévenir les infections."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pendant le traitement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de relaxation et un soutien psychologique peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Le cyclophosphamide est-il utilisé seul ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est souvent utilisé en combinaison avec d'autres agents chimiothérapeutiques."
}
},
{
"@type": "Question",
"name": "Comment le cyclophosphamide agit-il contre le cancer ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il interfère avec la réplication de l'ADN, inhibant la croissance des cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée varie selon le type de cancer, généralement plusieurs mois."
}
},
{
"@type": "Question",
"name": "Des médicaments sont-ils prescrits pour les effets secondaires ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antiémétiques et des antibiotiques peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "Le cyclophosphamide nécessite-t-il une hydratation ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une bonne hydratation est essentielle pour prévenir la toxicité rénale."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications à long terme ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des risques de cancers secondaires et de maladies cardiaques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le cyclophosphamide peut-il causer des problèmes cardiaques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut entraîner des cardiomyopathies, surtout à forte dose."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'infertilité ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le cyclophosphamide peut entraîner une infertilité temporaire ou permanente."
}
},
{
"@type": "Question",
"name": "Des troubles sanguins peuvent-ils survenir ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles comme l'anémie ou la leucopénie peuvent se développer."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers et des tests sanguins sont nécessaires pour détecter les complications."
}
},
{
"@type": "Question",
"name": "Qui est à risque de complications ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients âgés et ceux avec des antécédents médicaux complexes sont plus à risque."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le traitement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut aggraver les effets secondaires et diminuer l'efficacité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des interactions médicamenteuses à surveiller ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interagir avec le cyclophosphamide, augmentant les risques."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux de cancer sont-ils un facteur ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux peuvent augmenter le risque de cancers secondaires."
}
},
{
"@type": "Question",
"name": "Le statut immunitaire affecte-t-il le traitement ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un statut immunitaire affaibli augmente le risque d'effets secondaires."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 22/11/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
26391Showa Pharmaceutical University.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
26391Showa Pharmaceutical University.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
Division of Pharmacy, 38261Tokai University Medical Hospital.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
Division of Pharmacy, 38261Tokai University Medical Hospital.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
26391Showa Pharmaceutical University.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
Programa de Pós-Graduação em Patologia Ambiental e Experimental, Universidade Paulista (UNIP), São Paulo, Brazil.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
Programa de Pós-Graduação em Patologia Ambiental e Experimental, Universidade Paulista (UNIP), São Paulo, Brazil.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
Programa de Pós-Graduação em Patologia Ambiental e Experimental, Universidade Paulista (UNIP), São Paulo, Brazil.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
Departamento de Fisiopatologia, Instituto Butantan, São Paulo, Brazil.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
Programa de Pós-Graduação em Patologia Ambiental e Experimental, Universidade Paulista (UNIP), São Paulo, Brazil.
Publications dans "Cyclophosphamide" :
2 publications dans cette catégorie
Affiliations :
Programa de Pós-Graduação em Patologia Ambiental e Experimental, Universidade Paulista (UNIP), São Paulo, Brazil.
Publications dans "Cyclophosphamide" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Federal University of Paraná, Curitiba, Brazil dmesaf7@gmail.com souzaem@ufpr.br.
Publications dans "Cyclophosphamide" :
1 publication dans cette catégorie
Affiliations :
Department of Pathology, Federal University of Paraná, Curitiba, Brazil.
Publications dans "Cyclophosphamide" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Federal University of Paraná, Curitiba, Brazil.
Publications dans "Cyclophosphamide" :
1 publication dans cette catégorie
Affiliations :
Ceva Animal Health, Campinas, Brazil.
Publications dans "Cyclophosphamide" :
1 publication dans cette catégorie
Affiliations :
Department of Pathology, Federal University of Paraná, Curitiba, Brazil.
Publications dans "Cyclophosphamide" :
Cyclophosphamide and infliximab are recommended as induction therapies for severe Behçet's syndrome. Whether infliximab is safer and more effective than cyclophosphamide in treating severe Behçet's sy...
In this phase 2, Bayesian, multicenter randomized controlled trial, we assigned patients fulfilling the International Study Group's criteria for Behçet's syndrome who had major vascular or central ner...
Between May 2018 and April 2021, 52 patients with severe Behçet's syndrome (n=37 [71%] with vascular Behçet's syndrome and n=15 [29%] with neuro-Behçet's syndrome) were randomly assigned to receive ei...
Among patients with severe Behçet's syndrome, induction therapy with infliximab had a superior complete response rate at 22 weeks and fewer adverse events than induction with cyclophosphamide. (Funded...
Oligoasthenozoospermia is becoming a serious problem, but effective prevention or treatment is lacking. Hyperoside, one of the main active ingredients in traditional Chinese medicine, may be effective...
Cytomegalovirus reactivation (CMV-R) is a significant complication of allogeneic hematopoietic stem cell transplantation (allo-HCT), especially in human leukocyte antigen-haploidentical transplantatio...
We retrospectively analyzed 52 patients seropositive for CMV who underwent haplo-HCT with PTCy at our institution between January 2015 and June 2021 and compared patients who received LTV prophylaxis ...
The 100-day cumulative CMV-R incidence was lower in the LTV group than in the control group (17.2% vs 81.8%, p < 0.001). Multivariate analysis revealed that prophylactic LTV reduced the 100-day cumula...
Prophylactic LTV effectively prevents CMV-R in patients undergoing haplo-HCT for PTCy....
Cyclophosphamide (CYC) may be an effective treatment in patients who fail first line therapy for severe central nervous system (CNS) inflammatory disorders including CNS vasculitis, neuromyelitis opti...
Haploidentical hematopoietic cell transplantation (HCT) with post-transplantation cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis is associated with inferior overall survival (OS)...
Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a serious life-threatening complication. The granulocyte colony-stimulated factor mobilized donor lymphocyte infusions (...
To explore this possibility, a retrospective study was conducted. 20 patients relapsing after HSCT were administered 20 mg/kg/d cyclophosphamide(Cy)on day 3 (for matched related transplantation) or on...
With a median follow-up of 4.8 (0-37.1) months, the PDCy group had lower cumulative incidence of severe aGVHD (III-IV, 5 % vs 31 %, p = 0.02; II-IV, 25 % vs 52 %, p = 0.04), but no significant differe...
On the premise of safety, the PDCy regimen could effectively protest against severe aGVHD after gDLI while preserving therapeutic response rates. However, the research results still require verificati...
Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches t...
Tumor and blood samples of 154 patients from the ABCSG-34 trial were available (76 patients received four cycles of EC followed by four cycles of D; 78 patients get the reverse treatment sequence). Tu...
Initial treatment with four cycles of EC reduced circulating B and T cells by 94% and 45%, respectively. In contrast, no comparable effects on lymphocytes were observed in patients treated with initia...
The deleterious effect of EC on lymphocytes indicates strong immunosuppressive properties of this combination therapy. D, in contrast, has no effect on lymphocytes, but triggers the secretion of stimu...
High-dose total body irradiation (TBI) is considered a cornerstone of myeloablative conditioning for allogeneic stem cell transplantation (allo-SCT). We retrospectively compared the main outcomes of a...
Fifty-nine patients received cyclophosphamide (Cy)-TBI (13.5 Gy) and graft-versus-host disease (GVHD) prophylaxis with a calcineurin-inhibitor plus methrotrexate (CyTBI group) and 28 patients received...
Median follow-up for survivors was 82 and 22 months. The 12-month probability of overall survival and progression-free survival were similar (p = .18, p = .7). The incidence of Grades 2-4 and 3-4 acut...
The study confirms the safety and efficacy of a novel FluTBI-PTCy platform with reduced incidence of severe acute and chronic GVHD, and early improvement of NRM....
Cyclophosphamide, an oxazaphosphorine prodrug is frequently used in treatment of neuroblastoma, which is one of the most prevalent solid organ malignancies in infants and young children. Cytochrome P4...
Cyclophosphamide (CY) is a chemotherapeutic drug that is commonly used to treat malignancies of the ovary, breast, and hematology, as well as autoimmune disorders. As a cofactor of mitochondrial multi...